Janice M. Mehnert - Concepedia

Author

Janice M. Mehnert

Rutgers, The State University of New Jersey ORCID

Also Known As

Howard L. Kaufman, J. M. Mehnert, J. Mehnert, J.M. Mehnert, Janice M Mehnert, Janice M. Mehnert, Janice Mehnert, Kaufman, Howard L

109

Publications

6.3K

Citations

H-Index

Concepts

All Affiliations

Rutgers, The State University of New Jersey Rutgers Cancer Institute Dana-Farber Cancer Institute The University of Texas MD Anderson Cancer Center Institut Gustave Roussy

About

Janice M. Mehnert is an author at Rutgers, The State University of New Jersey specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2.5K
2	Immunology	16	17	2K
3	Cell Biology	3	3	627
4	Health Sciences	2	2	33
5	Hepatology	2	2	121

Janice M. Mehnert

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028 Patrick A. Ott, Yung‐Jue Bang, Sarina A. Piha‐Paul, Journal of Clinical Oncology	2018	965
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders Douglas B. Johnson, Ryan J. Sullivan, Patrick A. Ott, JAMA Oncology	2015	653
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study Patrick A. Ott, Yung‐Jue Bang, Dominique Berton-Rigaud, Journal of Clinical Oncology	2017	504
Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study Chiun Hsu, Se‐Hoon Lee, Samuel Ejadi, Journal of Clinical Oncology Keynote-028 StudySolid TumorsImmunologyImmunoeditingCell Death	2017	457
Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer Janice M. Mehnert, Anshuman Panda, Kim M. Hirshfield, Journal of Clinical Investigation Tumor BiologyImmune ActivationDna Polymerase EpsilonMedicineImmunology	2016	382
Autophagy maintains tumour growth through circulating arginine Laura Poillet-Perez, Xiaoqi Xie, Le Zhan, Nature Cell AutophagyMitophagyTumour GrowthAutophagyLipophagy	2018	368
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers Matteo Palmeri, Janice M. Mehnert, Ann W. Silk, ESMO Open	2021	333
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028 Andréa Varga, Sarina A. Piha‐Paul, Patrick A. Ott, Gynecologic Oncology Advanced Ovarian CancerMedicineImmunologyTumor ImmunityPathology	2018	269
Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-risk Resected Melanoma James R. Patrinely, Rebecca Johnson, Aleigha Lawless, JAMA Oncology	2021	235
Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Andréa Varga, Sarina A. Piha‐Paul, Patrick A. Ott, Journal of Clinical Oncology Antitumor ActivityImmunologyGynecologyPathologyPharmacotherapy	2015	155

Page 1